...
Page properties |
---|
Title | Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) Library Version 1.0 (PRO-CTCAE V1.0) |
---|
CDISC Reference | QuestionnaireSupplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials |
---|
QRS Short Name | |
---|
QRS Permission Status | Approved |
---|
Team | Pancreatic Cancer Therapeutic Area Team and CDISC Questionnaires, Ratings, and Scales (QRS) Subteam |
---|
Supplement Version | 1.0 |
---|
Status | DRAFT |
---|
Date | 2022-0304-3004 |
---|
Notes | This supplement is intended to be used with other CDISC user guides for specific therapeutic/disease areas and follows the CDISC Study Data Tabulation Model Implementation Guide for Human Clinical Trials. |
---|
|
...
Revision History
Date | Version |
---|
2022-0304-3004 | 1.0 Draft |
Info |
---|
The CDISC PRO-CTCAE V1.0 supplement version 1.0 was developed based on the NCI/NIH PRO-CTCAE® website. The website’s PRO-CTCAE Version 1.0 Release Notes indicate the revisions made by NCI/NIH on the PRO-CTCAE 1.0 instrumentmeasurement system. The instrument’s measurement system version is 1.0 based on the website's release notes (specific correction of typographical errors in the different CRF translations). NCI/NIH will notify CDISC of any major changes in the future that would require a change control to the CDISC PRO-CTCAE V1.0 supplement version. |
...
This document describes the CDISC implementation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) Item Library Version 1.0 (PRO-CTCAE V1.0) instrument.
CDISC did not modify this questionnaires, ratings, and scales (QRS) instrument measurement to meet Clinical Data Acquisition Standards Harmonization (CDASH) case report form (CRF) standards.
The representation of data collected for this instrument measurement is based on the Study Data Tabulation Model Implementation Guide (SDTMIG) Questionnaires (QS) domain model, which can be found at the CDISC website at: https://www.cdisc.org/standards/foundational/sdtmig.
These specific implementation details for this instrument measurement are meant to be used in conjunction with the SDTMIG. All instrument documentation All QRS documentation can be found on the CDISC web site at: https://www.cdisc.org/standards/foundational/qrs.
...
Although the United States Food and Drug Administration (US FDA) has provided input with regard to this supplement, this input does not constitute US FDA endorsement of any particular instrument.
2 Copyright Status
The NATIONAL CANCER INSTITUTE (NCI) at the NATIONAL INSTITUTES OF HEALTH (NIH) owns the copyright for the PRO-CTCAE V1.0 measurement system instrument and has made it exempt from copyright restrictions. Use of the PRO-CTCAE V1.0 is subject to NCI terms of use policy listed on the website. CDISC has included this supplement in the CDISC inventory of QRS data standards supplements. Hence, CDISC developed QSTESTCD and QSTEST for each item based on the actual text on the instrument measurement system.
The CDISC documentation of this instrument consists measurement system consists of: (1) controlled terminology, (2) standard database structure with examples, and (3) CRF(s) annotated with the CDISC SDTMIG variables with submission values.
...
CDISC has developed this documentation at no cost to copyright holder or any additional cost to users of the instrument beyond measurement system beyond the normal licenses fees charged by the copyright holder.
...
- These materials discuss and/or include the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library Version 1.0 Version Date 4/26/2020 (PRO-CTCAE V1.0) which is owned exclusively by the Division of Cancer Control and Population Sciences in the NATIONAL CANCER INSTITUTE at the NATIONAL INSTITUTES OF HEALTH (NCINational Cancer Institute (NCI) at the National Institutes of Health (NIH). No part of the PRO-CTCAE V1.0 may be reproduced, distributed, or transmitted in any form or by any means, including photocopying recording, or other electronic or mechanical methods, without the prior written permission of NCI and payment of any applicable fees. PRO-CTCAE V1.0 copyright, NATIONAL CANCER INSTITUTE at the NATIONAL INSTITUTES OF HEALTH (NCI)National Cancer Institute at the National Institutes of Health. All rights reserved.
- The PRO-CTCAE trademark items and information herein were developed by the Division of Cancer Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library Version 1.0 (PRO-CTCAE V1.0) (The PRO-CTCAE trademark items and information herein were developed by the Division of Cancer Control and Population Sciences in the NATIONAL CANCER INSTITUTE at the NATIONAL INSTITUTES OF HEALTHNational Cancer Institute at the National Institutes of Health, in Bethesda, Maryland, U.S.A. Use of the PRO-CTCAE is subject to NCI's NCI’s "Terms of Use". PRO-CTCAE Measurement System content should be downloaded using the "Instrument & Form Builder". https://healthcaredelivery.cancer.gov/protpro-ctcae/. ( Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).J Natl Cancer Inst 2014 Sept Sep 29;106(9)).
- [1] National Institutes of Health – National Cancer Institute, Division of Cancer Control & Population Sciences. (2017, July 2) https://healthcaredelivery.cancer.gov/pro-ctcae/overview.html
...
All assumptions and business rules described in the SDTMIG QS domain are applicable to this supplement. Additional assumptions specific to the PRO-CTCAE V1.0 are listed below.
The PRO-CTCAE V1.0measurement system is a patient-reported outcome (PRO) instrument developed to capture symptomatic adverse events of patients in cancer clinical trials. The PRO-CTCAE V1.0 was designed to be used in conjunction with the Common Terminology Criteria for Adverse Events (CTCAE).[1] It consists of an item library rather than a static/fixed question item type of instrument. You should This item library concept is different than other CDISC public domain and copyrighted specific QRS instruments. Users are directed to use the form builder as described on the PRO-CTCAE website to build CRFs and with instructions provided by NCI to select the items to implement it in your a clinical study. The PRO-CTCAE V1.0 includes multiple choice questions on the frequency, severity, interference, presence/absence and/or amount of specific adverse events.
Administration of PRO-CTCAE V1.0 may be conducted via different modes, including screen-based, interactive voice response, and paper. Electronic implementation of the PRO-CTCAE V1.0 instrument is measurement system is recommended by NCI/NIH.
- As a CDISC QRS standard, the instrument supplement name is PRO-CTCAE V1.0, as provided in this supplementdocument. As an item library, sponsors may select items from the overall library as a subset of items with the same CDISC Controlled Terminology as appropriate for the condition being studied. It is the users responsibility to identify the subset of items used from the overall PRO-CTCAE V1.0 Item Library (Version 1.0). The subsetted PRO-CTCAE V1.0 user's instrument should measurement system should be titled "PRO-CTCAE sponsor-specified symptoms..." based on the sponsor's discretion when they identify the specific items being used. This will distinctly describe the subsetted instrument from measurement system from the overall PRO-CTCAE V1.0.
For the PRO-CTCAE V1.0, QSORRES is populated represented with the text description while the numeric rating is represented in the standardized character and numeric result variables QSSTRESC and QSSTRESN. Please reference the PRO-CTCAE website FAQs for more details on the numeric responses. The responses for the PRO-CTCAE V1.0 are as follows:
- Depending on the symptomatic AE being measured, items assessing symptom presence/absence are rated as follows:
- Items assessing symptom presence/absence are rated on a binary response scale and rated from 0-1 (e.g., 0 = “No” and 1 = “Yes”);
- Items rated on multiple (more than two) response scale and rated from 0-1 (e.g., 0 = “No”, 1 = “Yes”, and “Not applicable” or "Not Applicable"); or);
- Items assessing symptom frequency are rated on a 5-point scale and are rated from 0-4 (e.g., 0 = “Never”, 1 = “Rarely”, 2 = “Occasionally”, 3 = “Frequently”, and 4 = “Almost constantly”).
- Items assessing symptom severity are rated on a 5-point scale rated from 0-4 (e.g., 0 = “None”, 1 = “Mild”, 2 = “Moderate”, 3 = “Severe”, and 4 = “Very severe”).
- QSTESTCD=PT01036A assessing symptom severity is rated on a 5-point scale rated from 0-4 (e.g., 0 = “None”, 1 = “Mild”, 2 = “Moderate”, 3 = “Severe”, and 4 = “Very severe”, Not applicable)
- Items assessing symptom interference Items assessing symptom amount are rated on a 5-point scale and are rated from 0-4 (e.g., 0 = “Not at all”, 1 = “A little bit”, 2 = “Somewhat”, 3 = “Quite a bit”, and 4 = “Very much”).
- Items assessing symptom frequency amount are rated on a 5-point scale and are rated from 0-4 (e.g., 0 = “Never”“Not at all”, 1 = “Rarely”“A little bit”, 2 = “Occasionally”“Somewhat”, 3 = “Frequently”“Quite a bit”, and 4 = “Almost constantly”“Very much”).
- QSTESTCD = "PT01066A " to "PT01071A" have specific responses .
- QSTESTCD=PT01069A and QSTESTCD=PT01070A assessing symptom presence/absence are rated on multiple (more than two) response scale and rated from 0-1 (e.g., 0 = “No”, 1 = “Yes”, “Not sexually active”, and “Prefer not to answer”).
QSTESTCD=PT01066A, PT01068A, and PT01071A Items assessing symptom severity are rated on a 5-point scale rated from 0-4 (e.g., 0 = “None”, 1 = “Mild”, 2 = “Moderate”, 3 = “Severe”, and 4 = “Very severe”, “Not applicable”, "Not sexually active", and “Prefer not to answer”).
- QSTESTCD = "PT01067A" assessing symptom frequency is rated on a 5-point scale rated from 0-4 (e.g., 0 = “Never”, 1 = “Rarely”, 2 = “Occasionally”, 3 = “Frequently”, and 4 = “Almost constantly”, "Not sexually active", and “Prefer not to answer”).
- Items assessing symptom interference are rated on a 5-point scale and are rated from 0-4 (e.g., 0 = “Not at all”, 1 = “A little bit”, 2 = “Somewhat”, 3 = “Quite a bit”, and 4 = “Very much”).
- The CRF represents up to 5 "other symptoms" to be recorded. In discussions with NIH, it was agreed to provide up to 10 "other symptoms" to be recorded if they existed. QSTESTCDs (QSTESTCDs "PT01082A" thru "PT0191A") and severity of the symptom at its worst (QSTESTCDs "PT01082B" thru "PT0191B").
- Total PRO-CTCAE V1.0 total scoring instructions have not yet been developed. Item-level scores are not combined (i.e., No total score nor symptom-specific scores are calculated.).
- The time period of evaluation for the PRO-CTCAE V1.0 is populated in the QSEVLINT field in ISO 8601 format when the evaluation interval can be precisely described as duration. The evaluation interval for the PRO-CTCAE V1.0 is the past 7 days (QSEVLINT = "-P7D". Please reference the PRO-CTCAE website for more details on the evaluation interval.
- Items are divided into 15 subcategories represented in the QSSCAT variable. These categorizations represent how the symptom terms are categorized in the PRO-CTCAE V1.0 Item Library (Version 1.0). See Section 4, SDTM Mapping Strategy, for a list of these subcategory values.
- The symptomatic AE being measured by a given item (e.g., the Symptom Term represented on the CRF corresponding to a given item) is stored in the SUPPQS dataset with the QNAM = "QSSYMPTM". This matches the symptom term identified in the PRO-CTCAE V1.0 Item Library (Version 1.0). The exception to this is the solicited verbatim symptom terms with QNAM = "OTHER SYMPTOMS".
Electronic conditional branching is recommended by NCI/NIH in the conduct of the PRO-CTCAE V1.0 for symptom terms that have two or more items. The logic branches from frequency, then to severity, then to interference. For example, if frequency is > (greater than) never, you next pose the severity question, and if severity>none, you pose the interference question. Please reference the PRO-CTCAE website for more details on the electronic conditional branching approach. In the conduct of the PRO-CTCAE V1.0 it expects responses for each item and there should be no missing responses. Electronic branched severity items are assigned responses of 0 = "None" and electronic branched interference items are assigned 0 = "Not al all".
- The language in which the PRO-CTCAE V1.0 was administered (e.g., English, Spanish, Japanese) is collected with the Form Builder application and may be represented as a supplemental qualifier with QNAM = "QSDCLANGQSLANGDC". Reference the PRO-CTCAE V1.0 website for a list of available language translations.
- Terminology
QSCAT, QSTESTCD, and QSTEST values are included in CDISC Controlled Terminology.
A full list of value sets for the qualifier, and result fields is provided in Section 4, SDTM Mapping Strategy.
...
The PRO-CTCAE V1.0 example below shows the terminology used to implement the instrument in measurement system in the QS domain. This example shows the data for 1 subject collected at the baseline visit for a PRO-CTCAE V1.0 instrument. The example uses CDISC Controlled Terminology for QSTESTCD, QSTEST, and QSCAT. All original results, matching the CRF item response text, are represented in QSORRES.This result is then represented as a standard numeric score in QSSTRESN and as a standard character representation in QSSTRESC.
...
The table represents the items from the PRO-CTCAE V1.0 instrument measurement system.
Dataset wrap |
---|
|
Rowcaps |
---|
Rows 20-21: | Represent the electronic conditional branching on data entry for the symptom hiccups did not occur and then the symptom of hiccups severity was assigned 0 = “None”. | Rows 24-26: | Represent the electronic conditional branching on data entry for the symptom abdominal pain frequency did not occur. The symptom of abdominal pain severity is assigned 0 = “None” and abdominal pain interference is assigned 0 = “Not at all”. | Rows 126-129: | Represent two additional symptoms that existed for the subject. | Rows 130-145: | Represent the symptoms "Other Symptom 3 and Other Symptom 3 Severity" through "Other Symptom 10 and Other Symptom 10 Severity" that did not exist for the subject. |
|
Dataset2 |
---|
Row | STUDYID | DOMAIN | USUBJID | QSSEQ | QSTESTCD | QSTEST | QSCAT | QSSCAT | QSORRES | QSSTRESC | QSSTRESN | QSLOBXFL | VISITNUM | QSDTC | QSEVLINT | 1 | STUDYX | QS | 23-P0001 | 1 | PT01001A | PT01-Dry Mouth Severity | PRO-CTCAE V1.0 | ORAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 2 | STUDYX | QS | 23-P0001 | 2 | PT01002A | PT01-Difficulty Swallowing Severity | PRO-CTCAE V1.0 | ORAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 3 | STUDYX | QS | 23-P0001 | 3 | PT01003A | PT01-Mouth/Throat Sores Severity | PRO-CTCAE V1.0 | ORAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 4 | STUDYX | QS | 23-P0001 | 4 | PT01003B | PT01-Mouth/Throat Sores Interference | PRO-CTCAE V1.0 | ORAL | A little bit | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 5 | STUDYX | QS | 23-P0001 | 5 | PT01004A | PT01-Cracking Corners of Mouth Severity | PRO-CTCAE V1.0 | ORAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 6 | STUDYX | QS | 23-P0001 | 6 | PT01005A | PT01-Voice Quality Changes Presence | PRO-CTCAE V1.0 | ORAL | No | 0 |
| Y | 1 | 2015-05-15 | -P7D | 7 | STUDYX | QS | 23-P0001 | 7 | PT01006A | PT01-Hoarseness Severity | PRO-CTCAE V1.0 | ORAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 8 | STUDYX | QS | 23-P0001 | 8 | PT01007A | PT01-Taste Changes Severity | PRO-CTCAE V1.0 | GASTROINTESTINAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 9 | STUDYX | QS | 23-P0001 | 9 | PT01008A | PT01-Decreased Appetite Severity | PRO-CTCAE V1.0 | GASTROINTESTINAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 10 | STUDYX | QS | 23-P0001 | 10 | PT01008B | PT01-Decreased Appetite Interference | PRO-CTCAE V1.0 | GASTROINTESTINAL | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 11 | STUDYX | QS | 23-P0001 | 11 | PT01009A | PT01-Nausea Frequency | PRO-CTCAE V1.0 | GASTROINTESTINAL | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 12 | STUDYX | QS | 23-P0001 | 12 | PT01009B | PT01-Nausea Severity | PRO-CTCAE V1.0 | GASTROINTESTINAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 13 | STUDYX | QS | 23-P0001 | 13 | PT01010A | PT01-Vomiting Frequency | PRO-CTCAE V1.0 | GASTROINTESTINAL | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 14 | STUDYX | QS | 23-P0001 | 14 | PT01010B | PT01-Vomiting Severity | PRO-CTCAE V1.0 | GASTROINTESTINAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 15 | STUDYX | QS | 23-P0001 | 15 | PT01011A | PT01-Heartburn Frequency | PRO-CTCAE V1.0 | GASTROINTESTINAL | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 16 | STUDYX | QS | 23-P0001 | 16 | PT01011B | PT01-Heartburn Severity | PRO-CTCAE V1.0 | GASTROINTESTINAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 17 | STUDYX | QS | 23-P0001 | 17 | PT01012A | PT01-Gas Presence | PRO-CTCAE V1.0 | GASTROINTESTINAL | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 18 | STUDYX | QS | 23-P0001 | 18 | PT01013A | PT01-Bloating Frequency | PRO-CTCAE V1.0 | GASTROINTESTINAL | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 19 | STUDYX | QS | 23-P0001 | 19 | PT01013B | PT01-Bloating Severity | PRO-CTCAE V1.0 | GASTROINTESTINAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 20 | STUDYX | QS | 23-P0001 | 20 | PT01014A | PT01-Hiccups Frequency | PRO-CTCAE V1.0 | GASTROINTESTINAL | Never | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 21 | STUDYX | QS | 23-P0001 | 21 | PT01014B | PT01-Hiccups Severity | PRO-CTCAE V1.0 | GASTROINTESTINAL | None | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 22 | STUDYX | QS | 23-P0001 | 22 | PT01015A | PT01-Constipation Severity | PRO-CTCAE V1.0 | GASTROINTESTINAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 23 | STUDYX | QS | 23-P0001 | 23 | PT01016A | PT01-Diarrhea Frequency | PRO-CTCAE V1.0 | GASTROINTESTINAL | Rarely | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 24 | STUDYX | QS | 23-P0001 | 24 | PT01017A | PT01-Abdominal Pain Frequency | PRO-CTCAE V1.0 | GASTROINTESTINAL | Never | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 25 | STUDYX | QS | 23-P0001 | 25 | PT01017B | PT01-Abdominal Pain Severity | PRO-CTCAE V1.0 | GASTROINTESTINAL | None | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 26 | STUDYX | QS | 23-P0001 | 26 | PT01017C | PT01-Abdominal Pain Interference | PRO-CTCAE V1.0 | GASTROINTESTINAL | Not at all | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 27 | STUDYX | QS | 23-P0001 | 27 | PT01018A | PT01-Fecal Incontinence Frequency | PRO-CTCAE V1.0 | GASTROINTESTINAL | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 28 | STUDYX | QS | 23-P0001 | 28 | PT01018B | PT01-Fecal Incontinence Interference | PRO-CTCAE V1.0 | GASTROINTESTINAL | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 29 | STUDYX | QS | 23-P0001 | 29 | PT01019A | PT01-Shortness of Breath Severity | PRO-CTCAE V1.0 | RESPIRATORY | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 30 | STUDYX | QS | 23-P0001 | 30 | PT01019B | PT01-Shortness of Breath Interference | PRO-CTCAE V1.0 | RESPIRATORY | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 31 | STUDYX | QS | 23-P0001 | 31 | PT01020A | PT01-Cough Severity | PRO-CTCAE V1.0 | RESPIRATORY | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 32 | STUDYX | QS | 23-P0001 | 32 | PT01020B | PT01-Cough Interference | PRO-CTCAE V1.0 | RESPIRATORY | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 33 | STUDYX | QS | 23-P0001 | 33 | PT01021A | PT01-Wheezing Severity | PRO-CTCAE V1.0 | RESPIRATORY | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 34 | STUDYX | QS | 23-P0001 | 34 | PT01022A | PT01-Swelling Frequency | PRO-CTCAE V1.0 | CARDIO/CIRCULATORY | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 35 | STUDYX | QS | 23-P0001 | 35 | PT01022B | PT01-Swelling Severity | PRO-CTCAE V1.0 | CARDIO/CIRCULATORY | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 36 | STUDYX | QS | 23-P0001 | 36 | PT01022C | PT01-Swelling Interference | PRO-CTCAE V1.0 | CARDIO/CIRCULATORY | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 37 | STUDYX | QS | 23-P0001 | 37 | PT01023A | PT01-Heart Palpitations Frequency | PRO-CTCAE V1.0 | CARDIO/CIRCULATORY | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 38 | STUDYX | QS | 23-P0001 | 38 | PT01023B | PT01-Heart Palpitations Severity | PRO-CTCAE V1.0 | CARDIO/CIRCULATORY | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 39 | STUDYX | QS | 23-P0001 | 39 | PT01024A | PT01-Rash Presence | PRO-CTCAE V1.0 | CUTANEOUS | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 40 | STUDYX | QS | 23-P0001 | 40 | PT01025A | PT01-Skin Dryness Severity | PRO-CTCAE V1.0 | CUTANEOUS | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 41 | STUDYX | QS | 23-P0001 | 41 | PT01026A | PT01-Acne Severity | PRO-CTCAE V1.0 | CUTANEOUS | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 42 | STUDYX | QS | 23-P0001 | 42 | PT01027A | PT01-Hair Loss Amount | PRO-CTCAE V1.0 | CUTANEOUS | Quite a bit | 3 | 3 | Y | 1 | 2015-05-15 | -P7D | 43 | STUDYX | QS | 23-P0001 | 43 | PT01028A | PT01-Itching Severity | PRO-CTCAE V1.0 | CUTANEOUS | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 44 | STUDYX | QS | 23-P0001 | 44 | PT01029A | PT01-Hives Presence | PRO-CTCAE V1.0 | CUTANEOUS | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 45 | STUDYX | QS | 23-P0001 | 45 | PT01030A | PT01-Hand-Foot Syndrome Severity | PRO-CTCAE V1.0 | CUTANEOUS | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 46 | STUDYX | QS | 23-P0001 | 46 | PT01031A | PT01-Nail Loss Presence | PRO-CTCAE V1.0 | CUTANEOUS | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 47 | STUDYX | QS | 23-P0001 | 47 | PT01032A | PT01-Nail Ridging Presence | PRO-CTCAE V1.0 | CUTANEOUS | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 48 | STUDYX | QS | 23-P0001 | 48 | PT01033A | PT01-Nail Discoloration Presence | PRO-CTCAE V1.0 | CUTANEOUS | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 49 | STUDYX | QS | 23-P0001 | 49 | PT01034A | PT01-Sensitivity to Sunlight Presence | PRO-CTCAE V1.0 | CUTANEOUS | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 50 | STUDYX | QS | 23-P0001 | 50 | PT01035A | PT01-Bed/Pressure Sores Presence | PRO-CTCAE V1.0 | CUTANEOUS | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 51 | STUDYX | QS | 23-P0001 | 51 | PT01036A | PT01-Radiation Skin Reaction Severity | PRO-CTCAE V1.0 | CUTANEOUS | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 52 | STUDYX | QS | 23-P0001 | 52 | PT01037A | PT01-Skin Darkening Presence | PRO-CTCAE V1.0 | CUTANEOUS | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 53 | STUDYX | QS | 23-P0001 | 53 | PT01038A | PT01-Stretch Marks Presence | PRO-CTCAE V1.0 | CUTANEOUS | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 54 | STUDYX | QS | 23-P0001 | 54 | PT01039A | PT01-Numbness & Tingling Severity | PRO-CTCAE V1.0 | NEUROLOGICAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 55 | STUDYX | QS | 23-P0001 | 55 | PT01039B | PT01-Numbness & Tingling Interference | PRO-CTCAE V1.0 | NEUROLOGICAL | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 56 | STUDYX | QS | 23-P0001 | 56 | PT01040A | PT01-Dizziness Severity | PRO-CTCAE V1.0 | NEUROLOGICAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 57 | STUDYX | QS | 23-P0001 | 57 | PT01040B | PT01-Dizziness Interference | PRO-CTCAE V1.0 | NEUROLOGICAL | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 58 | STUDYX | QS | 23-P0001 | 58 | PT01041A | PT01-Blurred Vision Severity | PRO-CTCAE V1.0 | VISUAL/PERCEPTUAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 59 | STUDYX | QS | 23-P0001 | 59 | PT01041B | PT01-Blurred Vision Interference | PRO-CTCAE V1.0 | VISUAL/PERCEPTUAL | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 60 | STUDYX | QS | 23-P0001 | 60 | PT01042A | PT01-Flashing Lights in Eyes Presence | PRO-CTCAE V1.0 | VISUAL/PERCEPTUAL | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 61 | STUDYX | QS | 23-P0001 | 61 | PT01043A | PT01-Visual Floaters Presence | PRO-CTCAE V1.0 | VISUAL/PERCEPTUAL | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 62 | STUDYX | QS | 23-P0001 | 62 | PT01044A | PT01-Watery Eyes Severity | PRO-CTCAE V1.0 | VISUAL/PERCEPTUAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 63 | STUDYX | QS | 23-P0001 | 63 | PT01044B | PT01-Watery Eyes Interference | PRO-CTCAE V1.0 | VISUAL/PERCEPTUAL | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 64 | STUDYX | QS | 23-P0001 | 64 | PT01045A | PT01-Ringing in Ears Severity | PRO-CTCAE V1.0 | VISUAL/PERCEPTUAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 65 | STUDYX | QS | 23-P0001 | 65 | PT01046A | PT01-Concentration Problems Severity | PRO-CTCAE V1.0 | ATTENTION/MEMORY | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 66 | STUDYX | QS | 23-P0001 | 66 | PT01046B | PT01-Concentration Problems Interference | PRO-CTCAE V1.0 | ATTENTION/MEMORY | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 67 | STUDYX | QS | 23-P0001 | 67 | PT01047A | PT01-Memory Problems Severity | PRO-CTCAE V1.0 | ATTENTION/MEMORY | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 68 | STUDYX | QS | 23-P0001 | 68 | PT01047B | PT01-Memory Problems Interference | PRO-CTCAE V1.0 | ATTENTION/MEMORY | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 69 | STUDYX | QS | 23-P0001 | 69 | PT01048A | PT01-General Pain Frequency | PRO-CTCAE V1.0 | PAIN | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 70 | STUDYX | QS | 23-P0001 | 70 | PT01048B | PT01-General Pain Severity | PRO-CTCAE V1.0 | PAIN | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 71 | STUDYX | QS | 23-P0001 | 71 | PT01048C | PT01-General Pain Interference | PRO-CTCAE V1.0 | PAIN | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 72 | STUDYX | QS | 23-P0001 | 72 | PT01049A | PT01-Headache Frequency | PRO-CTCAE V1.0 | PAIN | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 73 | STUDYX | QS | 23-P0001 | 73 | PT01049B | PT01-Headache Severity | PRO-CTCAE V1.0 | PAIN | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 74 | STUDYX | QS | 23-P0001 | 74 | PT01049C | PT01-Headache Interference | PRO-CTCAE V1.0 | PAIN | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 75 | STUDYX | QS | 23-P0001 | 75 | PT01050A | PT01-Muscle Pain Frequency | PRO-CTCAE V1.0 | PAIN | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 76 | STUDYX | QS | 23-P0001 | 76 | PT01050B | PT01-Muscle Pain Severity | PRO-CTCAE V1.0 | PAIN | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 77 | STUDYX | QS | 23-P0001 | 77 | PT01050C | PT01-Muscle Pain Interference | PRO-CTCAE V1.0 | PAIN | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 78 | STUDYX | QS | 23-P0001 | 78 | PT01051A | PT01-Joint Pain Frequency | PRO-CTCAE V1.0 | PAIN | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 79 | STUDYX | QS | 23-P0001 | 79 | PT01051B | PT01-Joint Pain Severity | PRO-CTCAE V1.0 | PAIN | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 80 | STUDYX | QS | 23-P0001 | 80 | PT01051C | PT01-Joint Pain Interference | PRO-CTCAE V1.0 | PAIN | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 81 | STUDYX | QS | 23-P0001 | 81 | PT01052A | PT01-Insomnia Severity | PRO-CTCAE V1.0 | SLEEP/WAKE | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 82 | STUDYX | QS | 23-P0001 | 82 | PT01052B | PT01-Insomnia Interference | PRO-CTCAE V1.0 | SLEEP/WAKE | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 83 | STUDYX | QS | 23-P0001 | 83 | PT01053A | PT01-Fatigue Severity | PRO-CTCAE V1.0 | SLEEP/WAKE | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 84 | STUDYX | QS | 23-P0001 | 84 | PT01053B | PT01-Fatigue Interference | PRO-CTCAE V1.0 | SLEEP/WAKE | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 85 | STUDYX | QS | 23-P0001 | 85 | PT01054A | PT01-Anxious Frequency | PRO-CTCAE V1.0 | MOOD | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 86 | STUDYX | QS | 23-P0001 | 86 | PT01054B | PT01-Anxious Severity | PRO-CTCAE V1.0 | MOOD | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 87 | STUDYX | QS | 23-P0001 | 87 | PT01054C | PT01-Anxious Interference | PRO-CTCAE V1.0 | MOOD | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 88 | STUDYX | QS | 23-P0001 | 88 | PT01055A | PT01-Discouraged Frequency | PRO-CTCAE V1.0 | MOOD | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 89 | STUDYX | QS | 23-P0001 | 89 | PT01055B | PT01-Discouraged Severity | PRO-CTCAE V1.0 | MOOD | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 90 | STUDYX | QS | 23-P0001 | 90 | PT01055C | PT01-Discouraged Interference | PRO-CTCAE V1.0 | MOOD | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 91 | STUDYX | QS | 23-P0001 | 91 | PT01056A | PT01-Sad Frequency | PRO-CTCAE V1.0 | MOOD | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 92 | STUDYX | QS | 23-P0001 | 92 | PT01056B | PT01-Sad Severity | PRO-CTCAE V1.0 | MOOD | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 93 | STUDYX | QS | 23-P0001 | 93 | PT01056C | PT01-Sad Interference | PRO-CTCAE V1.0 | MOOD | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 94 | STUDYX | QS | 23-P0001 | 94 | PT01057A | PT01-Irregular Menstrual Period Presence | PRO-CTCAE V1.0 | GYNECOLOGIC/URINARY | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 95 | STUDYX | QS | 23-P0001 | 95 | PT01058A | PT01-Missed Menstrual Period Presence | PRO-CTCAE V1.0 | GYNECOLOGIC/URINARY | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 96 | STUDYX | QS | 23-P0001 | 96 | PT01059A | PT01-Vaginal Discharge Amount | PRO-CTCAE V1.0 | GYNECOLOGIC/URINARY | Somewhat | 2 |
| Y | 1 | 2015-05-15 | -P7D | 97 | STUDYX | QS | 23-P0001 | 97 | PT01060A | PT01-Vaginal Dryness Severity | PRO-CTCAE V1.0 | GYNECOLOGIC/URINARY | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 98 | STUDYX | QS | 23-P0001 | 98 | PT01061A | PT01-Painful Urination Severity | PRO-CTCAE V1.0 | GYNECOLOGIC/URINARY | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 99 | STUDYX | QS | 23-P0001 | 99 | PT01062A | PT01-Urinary Urgency Frequency | PRO-CTCAE V1.0 | GYNECOLOGIC/URINARY | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 100 | STUDYX | QS | 23-P0001 | 100 | PT01062B | PT01-Urinary Urgency Interference | PRO-CTCAE V1.0 | GYNECOLOGIC/URINARY | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 191 | STUDYX | QS | 23-P0001 | 191 | PT01063A | PT01-Urinary Frequency Frequency | PRO-CTCAE V1.0 | GYNECOLOGIC/URINARY | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 102 | STUDYX | QS | 23-P0001 | 102 | PT01063B | PT01-Urinary Frequency Interference | PRO-CTCAE V1.0 | GYNECOLOGIC/URINARY | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 103 | STUDYX | QS | 23-P0001 | 103 | PT01064A | PT01-Urine Color Change Presence | PRO-CTCAE V1.0 | GYNECOLOGIC/URINARY | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 104 | STUDYX | QS | 23-P0001 | 104 | PT01065A | PT01-Urinary Incontinence Frequency | PRO-CTCAE V1.0 | GYNECOLOGIC/URINARY | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 105 | STUDYX | QS | 23-P0001 | 105 | PT01065B | PT01-Urinary Incontinence Interference | PRO-CTCAE V1.0 | GYNECOLOGIC/URINARY | Somewhat | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 106 | STUDYX | QS | 23-P0001 | 106 | PT01066A | PT01-Achieve&Maintain Erection Severity | PRO-CTCAE V1.0 | SEXUAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 107 | STUDYX | QS | 23-P0001 | 107 | PT01067A | PT01-Ejaculation Frequency | PRO-CTCAE V1.0 | SEXUAL | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 108 | STUDYX | QS | 23-P0001 | 108 | PT01068A | PT01-Decreased Libido Severity | PRO-CTCAE V1.0 | SEXUAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 109 | STUDYX | QS | 23-P0001 | 109 | PT01069A | PT01-Delayed Orgasm Presence | PRO-CTCAE V1.0 | SEXUAL | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 110 | STUDYX | QS | 23-P0001 | 110 | PT01070A | PT01-Unable to Have Orgasm Presence | PRO-CTCAE V1.0 | SEXUAL | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 111 | STUDYX | QS | 23-P0001 | 111 | PT01071A | PT01-Pain w/Sexual Intercourse Severity | PRO-CTCAE V1.0 | SEXUAL | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 112 | STUDYX | QS | 23-P0001 | 112 | PT01072A | PT01-Breast Swelling&Tenderness Severity | PRO-CTCAE V1.0 | MISCELLANEOUS | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 113 | STUDYX | QS | 23-P0001 | 113 | PT01073A | PT01-Bruising Presence | PRO-CTCAE V1.0 | MISCELLANEOUS | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 114 | STUDYX | QS | 23-P0001 | 114 | PT01074A | PT01-Chills Frequency | PRO-CTCAE V1.0 | MISCELLANEOUS | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 115 | STUDYX | QS | 23-P0001 | 115 | PT01074B | PT01-Chills Severity | PRO-CTCAE V1.0 | MISCELLANEOUS | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 116 | STUDYX | QS | 23-P0001 | 116 | PT01075A | PT01-Increased Sweating Frequency | PRO-CTCAE V1.0 | MISCELLANEOUS | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 117 | STUDYX | QS | 23-P0001 | 117 | PT01075B | PT01-Increased Sweating Severity | PRO-CTCAE V1.0 | MISCELLANEOUS | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 118 | STUDYX | QS | 23-P0001 | 118 | PT01076A | PT01-Decreased Sweating Presence | PRO-CTCAE V1.0 | MISCELLANEOUS | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 118 | STUDYX | QS | 23-P0001 | 118 | PT01077A | PT01-Hot Flashes Frequency | PRO-CTCAE V1.0 | MISCELLANEOUS | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 120 | STUDYX | QS | 23-P0001 | 120 | PT01077B | PT01-Hot Flashes Severity | PRO-CTCAE V1.0 | MISCELLANEOUS | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 121 | STUDYX | QS | 23-P0001 | 121 | PT01078A | PT01-Nosebleed Frequency | PRO-CTCAE V1.0 | MISCELLANEOUS | Occasionally | 2 | 2 | Y | 1 | 2015-05-15 | -P7D | 122 | STUDYX | QS | 23-P0001 | 122 | PT01078B | PT01-Nosebleed Severity | PRO-CTCAE V1.0 | MISCELLANEOUS | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 123 | STUDYX | QS | 23-P0001 | 123 | PT01079A | PT01-Pain&Swelling at Inj Site Presence | PRO-CTCAE V1.0 | MISCELLANEOUS | No | 0 | 0 | Y | 1 | 2015-05-15 | -P7D | 124 | STUDYX | QS | 23-P0001 | 124 | PT01080A | PT01-Body Odor Severity | PRO-CTCAE V1.0 | MISCELLANEOUS | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 125 | STUDYX | QS | 23-P0001 | 125 | PT01081 | PT01-Any Other Symptoms Reported | PRO-CTCAE V1.0 | OTHER SYMPTOMS | Yes | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 126 | STUDYX | QS | 23-P0001 | 126 | PT01082A | PT01-Other Symptom 1 | PRO-CTCAE V1.0 | OTHER SYMPTOMS | Another symptom 1 | Another symptom 1 |
| Y | 1 | 2015-05-15 | -P7D | 127 | STUDYX | QS | 23-P0001 | 127 | PT01082B | PT01-Other Symptom 1 Severity | PRO-CTCAE V1.0 | OTHER SYMPTOMS | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 128 | STUDYX | QS | 23-P0001 | 128 | PT01083A | PT01-Other Symptom 2 | PRO-CTCAE V1.0 | OTHER SYMPTOMS | Another symptom 2 | Another symptom 2 |
| Y | 1 | 2015-05-15 | -P7D | 129 | STUDYX | QS | 23-P0001 | 129 | PT01083B | PT01-Other Symptom 2 Severity | PRO-CTCAE V1.0 | OTHER SYMPTOMS | Mild | 1 | 1 | Y | 1 | 2015-05-15 | -P7D | 130 | STUDYX | QS | 23-P0001 | 130 | PT01084A | PT01-Other Symptom 3 | PRO-CTCAE V1.0 | OTHER SYMPTOMS |
|
|
| Y | 1 | 2015-05-15 | -P7D | 131 | STUDYX | QS | 23-P0001 | 131 | PT01084B | PT01-Other Symptom 3 Severity | PRO-CTCAE V1.0 | OTHER SYMPTOMS |
|
|
| Y | 1 | 2015-05-15 | -P7D | 132 | STUDYX | QS | 23-P0001 | 132 | PT01085A | PT01-Other Symptom 4 | PRO-CTCAE V1.0 | OTHER SYMPTOMS |
|
|
| Y | 1 | 2015-05-15 | -P7D | 133 | STUDYX | QS | 23-P0001 | 133 | PT01085B | PT01-Other Symptom 4 Severity | PRO-CTCAE V1.0 | OTHER SYMPTOMS |
|
|
| Y | 1 | 2015-05-15 | -P7D | 134 | STUDYX | QS | 23-P0001 | 134 | PT01086A | PT01-Other Symptom 5 | PRO-CTCAE V1.0 | OTHER SYMPTOMS |
|
|
| Y | 1 | 2015-05-15 | -P7D | 135 | STUDYX | QS | 23-P0001 | 135 | PT01086B | PT01-Other Symptom 5 Severity | PRO-CTCAE V1.0 | OTHER SYMPTOMS |
|
|
| Y | 1 | 2015-05-15 | -P7D | 136 | STUDYX | QS | 23-P0001 | 136 | PT01087A | PT01-Other Symptom 6 | PRO-CTCAE V1.0 | OTHER SYMPTOMS |
|
|
| Y | 1 | 2015-05-15 | -P7D | 137 | STUDYX | QS | 23-P0001 | 137 | PT01087B | PT01-Other Symptom 6 Severity | PRO-CTCAE V1.0 | OTHER SYMPTOMS |
|
|
| Y | 1 | 2015-05-15 | -P7D | 138 | STUDYX | QS | 23-P0001 | 138 | PT01088A | PT01-Other Symptom 7 | PRO-CTCAE V1.0 | OTHER SYMPTOMS |
|
|
| Y | 1 | 2015-05-15 | -P7D | 139 | STUDYX | QS | 23-P0001 | 139 | PT01088B | PT01-Other Symptom 7 Severity | PRO-CTCAE V1.0 | OTHER SYMPTOMS |
|
|
| Y | 1 | 2015-05-15 | -P7D | 140 | STUDYX | QS | 23-P0001 | 140 | PT01089A | PT01-Other Symptom 8 | PRO-CTCAE V1.0 | OTHER SYMPTOMS |
|
|
| Y | 1 | 2015-05-15 | -P7D | 141 | STUDYX | QS | 23-P0001 | 141 | PT01089B | PT01-Other Symptom 8 Severity | PRO-CTCAE V1.0 | OTHER SYMPTOMS |
|
|
| Y | 1 | 2015-05-15 | -P7D | 142 | STUDYX | QS | 23-P0001 | 142 | PT01090A | PT01-Other Symptom 9 | PRO-CTCAE V1.0 | OTHER SYMPTOMS |
|
|
| Y | 1 | 2015-05-15 | -P7D | 143 | STUDYX | QS | 23-P0001 | 143 | PT01090B | PT01-Other Symptom 9 Severity | PRO-CTCAE V1.0 | OTHER SYMPTOMS |
|
|
| Y | 1 | 2015-05-15 | -P7D | 144 | STUDYX | QS | 23-P0001 | 144 | PT01091A | PT01-Other Symptom 10 | PRO-CTCAE V1.0 | OTHER SYMPTOMS |
|
|
| Y | 1 | 2015-05-15 | -P7D | 145 | STUDYX | QS | 23-P0001 | 145 | PT01091B | PT01-Other Symptom 10 Severity | PRO-CTCAE V1.0 | OTHER SYMPTOMS |
|
|
| Y | 1 | 2015-05-15 | -P7D |
|
|
...
This section is used for reference regarding the CRF data capture and to understand the alignment of the instrument to measurement system to the SDTM QS domain. It also provides guidance on how the result variables (QSORRES, QSSTRESC, and QSSTRESN) should be populated.
...
PRO-CTCAE V1.0 supported languages
QNAM | QLABEL | QVAL |
QSDCLANGQSLANGDC | Data Collection Language | CHINESE |
|
| CZECH |
|
| DANISH |
|
| DUTCH |
|
| ENGLISH |
|
| FRENCH |
|
| GERMAN |
|
| GREEK |
|
| HUNGARIAN |
|
| ITALIAN |
|
| JAPANESE |
|
| KOREAN |
|
| POLISH |
|
| PORTUGUESE |
|
| RUSSIAN |
|
| SPANISH |
...